AGY.L Stock Analysis
AG
Uncovered
Allergy Therapeutics PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.264
Dividend yield
—
Shares outstanding
679.1 B
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The firm sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. The company operates in Austria, Germany, Italy, Netherlands, Spain, Switzerland and United Kingdom.